Compare Godaddy Inc (GDDY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs TransMedics Group Inc — how do they compare? Godaddy Inc trades at $104.37 (market cap $13.07B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Godaddy Inc is far larger — about 4.8× TransMedics Group Inc's market cap, and Godaddy Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and TransMedics Group Inc for 24 Days on average.
| GDDY | TMDX | |
|---|---|---|
Market Cap | $13.07B | $2.74B |
Volume | 1,831,274 | 949,331 |
Sector | Technology | Health |
52-Week High | $135.18 | $150.42 |
52-Week Low | $75.07 | $61.99 |
Typical Hold Time | 64 Days | 24 Days |
Enterprise Value | $15.75B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.37, up 7.37% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and revenue growth to $4.95 billion in 2025. However, a class action lawsuit filed in September 2026 alleging securities fraud during September 2025 to February 2026 has created negative sentiment, though analyst consensus remains predominantly buy-rated.
The outlook is mixed; strong profitability and consistent earnings beats support upside potential, but legal risks and a current price above the $96.20 consensus target warrant caution. Key risks include litigation outcomes and competitive pressures in web services, while institutional analyst support at 57.9% buy ratings provides a cushion against near-term volatility.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
